Zobrazeno 1 - 10
of 230
pro vyhledávání: '"John F. Greden"'
Autor:
Boadie W. Dunlop, Sagar V. Parikh, Anthony J. Rothschild, Michael E. Thase, Charles DeBattista, Charles R. Conway, Brent P. Forester, Francis M. Mondimore, Richard C. Shelton, Matthew Macaluso, Jennifer Logan, Paul Traxler, James Li, Holly Johnson, John F. Greden
Publikováno v:
BMC Psychiatry, Vol 19, Iss 1, Pp 1-10 (2019)
Abstract Background Previous research suggests that the 17-item Hamilton Depression Rating Scale (HAM-D17) is less sensitive in detecting differences between active treatment and placebo for major depressive disorder (MDD) than is the HAM-D6 scale, w
Externí odkaz:
https://doaj.org/article/f409e8fbf79f4da4bc9f7fe2654e8e0f
Autor:
John F. Greden, Sagar V. Parikh, Danielle S. Taubman, Stephanie Salazar, Lizelle Salazar, Will Heininger, Michelle Riba
Publikováno v:
Academic Psychiatry
Autor:
Rajiv, Tandon, John F, Greden
Publikováno v:
Schizophrenia Research. 242:42-44
Autor:
Jane L. Pearson, Maria A. Oquendo, Kathy Shear, Myrna M. Weissman, Steve Zalcman, Chip Reynolds, Ray DePaulo, Katie A. Busch, Matt Rudorfer, Christine Moutier, Bob Hirschfield, John F. Greden, Sid Zisook, Murray B. Stein, John E. Rush, Jan Fawcett, Jill M. Harkavy-Friedman, Barry D. Lebowitz, Maria Kovacs, Naomi M. Simon
Publikováno v:
Depression and Anxiety. 38:1004-1006
Autor:
Charles R. Conway, Boadie W. Dunlop, Matthew Macaluso, Paul Traxler, Anthony J. Rothschild, Michael E. Thase, Charles DeBattista, Sagar V. Parikh, James Li, Jennifer Logan, Lisa M. Brown, Sara L. Weisenbach, Olusola Ajilore, Richard C. Shelton, Bryan Dechairo, Brent P. Forester, Ipsit V. Vahia, John F. Greden
Publikováno v:
Focus (Am Psychiatr Publ)
Objective Evaluate the clinical utility of combinatorial pharmacogenomic testing for informing medication selection among older adults who have experienced antidepressant medication failure for major depressive disorder (MDD). Design Post hoc analysi
Autor:
Sudhakar Selvaraj, Christopher D. Schneck, Carolyn Turvey, Olusola Ajilore, J. Raymond DePaulo, Sophie A. Lazarus, David J. Katzelnick, Paresh D. Patel, Peter P. Zandi, Valeria A. Cuellar, Patricia Dill Rinvelt, Yu Hsun Wang, William Coryell, Constance Guille, Jesse H. Wright, Erika F.H. Saunders, John F. Greden
Publikováno v:
Psychiatric Services. 71:456-464
Mood disorders are among the most burdensome public health concerns. The National Network of Depression Centers (NNDC) is a nonprofit consortium of 26 leading clinical and academic member centers in the United States providing care for patients with
Publikováno v:
Focus (Am Psychiatr Publ)
According to the World Health Organization, major depressive disorder is the world’s leading cause of disability. If clinical remission is not attained and sustained, episodes tend to recur with greater severity and with lessening responsivity to c
Autor:
Jess G, Fiedorowicz, Lisa, Brown, James, Li, Sagar V, Parikh, Boadie W, Dunlop, Brent P, Forester, Richard C, Shelton, Michael E, Thase, Matthew, Macaluso, Kunbo, Yu, John F, Greden
Publikováno v:
Psychopharmacol Bull
Weight gain is a common side-effect of medications used to treat major depressive disorder (MDD). We sought to estimate the frequency of weight gain for obesogenic medications prescribed for MDD and to evaluate if bupropion mitigated risk for weight
Autor:
Sagar V, Parikh, Daniela, Lopez, Jennifer L, Vande Voort, Jose, Rico, Eric, Achtyes, William, Coryell, Andrew, Goddard, Fernando, Goes, John F, Greden, Balwinder, Singh, Adam, Kaplin, Mark A, Frye, Daniel, Maixner, Brendon, Watson, Karina, Drake, Vijay, Tarnal, Patricio, Riva-Posse, William V, Bobo, Bio-K Study Team
Publikováno v:
Psychopharmacol Bull
The efficacy of subanesthetic intravenous ketamine for treatment resistant depression (TRD) has spurred a growth of clinics nationwide that provide this service. Ketamine is an FDA-approved drug as an anesthetic but remains unapproved for psychiatric
Autor:
Sagar V. Parikh, Rebecca A. Law, Daniel T. Hain, Anthony J. Rothschild, Michael E. Thase, Boadie W. Dunlop, Charles DeBattista, Brent P. Forester, Richard C. Shelton, Matthew Macaluso, Elizabeth S. Cogan, Krystal Brown, David J. Lewis, Michael R. Jablonski, John F. Greden
Publikováno v:
Psychiatry research. 308
Pharmacogenomic testing can be used to guide medication selection in patients with major depressive disorder (MDD). Currently, there is no consensus on which gene or genes to consider in medication management. Here, we assessed the clinical validity